Argireline
Also written as acetyl hexapeptide-8, acetyl hexapeptide-3, Ac-EEMQRR-NH₂
Argireline was rationally designed to interfere with the same vesicle-fusion machinery that botulinum toxin attacks. Two randomised trials show measurable wrinkle improvement — and its own discovery paper notes it is far less effective than the toxin.
- Sequence
- Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂
- Residues
- 6
- Mass
- ≈889 Da
- Origin
- Designed to mimic the N-terminal end of SNAP-25
- Best evidence
- L4 — Controlled trials
- US status
- Cosmetic ingredient; not a drug
- Anti-doping
- Not applicable
- Reviewed
- 8 October 2026
What it is
Argireline is a six-residue synthetic peptide, acetylated at one end and amidated at the other, patterned on the N-terminal region of SNAP-25. SNAP-25 is one of the three proteins that form the SNARE complex, the machinery a nerve cell uses to fuse a neurotransmitter vesicle with its membrane and release its contents.
Botulinum neurotoxin works by cleaving SNAP-25. Argireline was designed, through a rational-design programme, to compete with it — not by cutting anything, but by interfering with the formation or stability of the SNARE complex, so that calcium-dependent release is impaired. Its original name in cosmetic ingredient lists was acetyl hexapeptide-3; the current INCI name is acetyl hexapeptide-8. Both refer to the same molecule, which is a common source of confusion when comparing product labels.
What it does in the body
In the discovery work, Argireline significantly inhibited neurotransmitter release with a potency similar to botulinum toxin A — but, as the authors themselves stated, with much lower efficacy. That distinction is the whole story of this ingredient and it is almost always dropped in marketing. Potency describes the concentration at which an effect begins; efficacy describes how large the maximum effect is. Argireline starts acting at comparable concentrations and then plateaus at a fraction of the toxin’s effect.
It showed no oral toxicity in vivo and no primary irritation at high doses, which is what you would hope for in something designed as a cosmetic alternative to an injected neurotoxin.
What the human evidence shows
Three human studies matter.
- Discovery study (2002). An oil-in-water emulsion containing 10% of the hexapeptide reduced wrinkle depth by up to 30% over 30 days in healthy women volunteers, assessed by skin topography analysis. Small, and not placebo-controlled in the modern sense.
- Randomised trial in Chinese subjects (2013). Sixty participants randomised 3:1 to Argireline or placebo, applied to periorbital wrinkles twice daily for four weeks. Subjective global assessment gave total anti-wrinkle efficacy of 48.9% versus 0% on placebo. Objectively, silicone replicas of the treated area analysed by a wrinkle-analysis apparatus showed all roughness parameters decreased in the Argireline group (p<0.01) with no obvious decrease on placebo.
- Combination study (2017). Twenty-four volunteers randomised across four arms for 60 days. The authors concluded that the results confirmed the anti-wrinkle activity of acetyl hexapeptide-3, and also found a significant decrease in transepidermal water loss with it — a barrier-function effect that was not the expected mechanism.
The honest version of the comparison
Argireline measurably reduces the appearance of expression lines in randomised studies. It does so to an extent appropriate to a cream, by a mechanism that is genuinely related to how botulinum toxin works, at a fraction of the effect size. Calling it “Botox in a jar” overstates it by a wide margin; calling it inert understates it.
Claims and what backs them
| Claim as usually stated | Verdict | What the published evidence actually shows |
|---|---|---|
| Reduces the appearance of expression lines | Supported | Two randomised studies with objective instrumentation (silicone replica roughness analysis) found significant reductions. Effect sizes are cosmetic in scale. |
| Works like botulinum toxin | Mixed | The mechanism is genuinely related — interference with SNARE complex formation rather than cleavage of SNAP-25. But the discovery paper states efficacy is much lower than the neurotoxin’s. |
| A needle-free alternative to injections | Not supported | No head-to-head trial against botulinum toxin exists, and the mechanism comparison above makes equivalence implausible. The two are not interchangeable. |
| Improves skin hydration and barrier function | Mixed | A significant reduction in transepidermal water loss was reported in the 2017 randomised study. Single finding, 24 participants, not the primary mechanism. |
| Penetrates to the neuromuscular junction | Unproven | A charged, hydrophilic hexapeptide crossing the stratum corneum in meaningful quantity is the central open question. The clinical results imply something happens; the delivery has not been quantified in human skin. |
Risks and unknowns
Safety profile is reassuring for topical use. No oral toxicity and no primary irritation at high doses in the original characterisation; no significant adverse events reported in the randomised trials. Ordinary cosmetic irritation remains possible and is usually about the formulation.
Delivery, again. Every rational objection to Argireline reduces to penetration. Unlike pal-KTTKS, it is not lipid-modified, so there is no obvious mechanism for crossing the barrier. Published studies measuring intact hexapeptide reaching dermal nerve terminals in human skin are not available.
Concentration and vehicle. The discovery study used a 10% emulsion. Commercial products vary enormously and often disclose nothing. “Contains acetyl hexapeptide-8” tells you the ingredient is present, not that it is present at a tested level.
Where regulators stand
The bottom line
Argireline is a well-characterised molecule with a real, specific mechanism and two randomised trials showing measurable improvement in the appearance of fine expression lines. That is a stronger position than most cosmetic actives occupy.
The marketing comparison to injectable neurotoxins is not supported by the molecule’s own discovery paper, which explicitly notes much lower efficacy. Expect a cream-sized effect, and notice that the open question is not whether the peptide can block vesicle fusion — it can, in a dish — but whether enough of it ever gets to where that would matter.
References
- Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303–310 PMID 18498523
- Wang Y, Wang M, Xiao S, et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147–153 PMID 23417317
- Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, randomized controlled study. J Cosmet Dermatol. 2017;16(2):271–278 PMID 28150423
- Nukaly HY, Halawani IR, Irtaza HM, et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2026;13:1618306 PMID 41924746